Oral antiviral treatments for COVID-19 Prescribing information for GPs

Lagevrio (molnupiravir)

Adults who have mild to moderate COVID-19 confirmed by a PCR or medically verified RAT and who can start treatment within five days of symptom onset, can be prescribed PBS-subsidised Lagevrio if:

  • they are 65 years of age or older, with two other risk factors for severe disease (as increasing age is a risk factor, patients who are 75 years of age of older only need to have one other risk factor); or
  • they identify as Aboriginal or Torres Strait Islander origin, and are 50 years of age or older with two other risk factors for severe disease, or
  • they are moderately to severely immunocompromised.

When prescribing Lagevrio via the PBS, ensure the patient meets the eligibility criteria outlined on the PBS listing.

You can review the National COVID-19 Clinical Evidence Taskforce recommendations for the use of Lagevrio here which includes that Lagevrio should be considered “…where other treatments (such as sotrovimab or nirmatrelvir plus ritonavir [Paxlovid]) are not suitable or available.”

The standard dose of Lagevrio is 800 mg (administered as four 200 mg capsules), taken every 12 hours for five days, with or without food.

Lagevrio should be taken regularly at the same time each day. If a dose is missed and it has been less than 10 hours since the last dose the patient can take it as soon as it is remembered. If it has been more than 10 hours since the missed dose this should be skipped, and the next dose taken at the scheduled time. A double dose should not be taken to make up for a missed dose. Patients should not stop taking Lagevrio without speaking to their GP or physician.

The capsules should not be opened, broken or crushed, and must be swallowed whole.

A person should not take Lagevrio if they are allergic to molnupiravir or any of the other ingredients listed in the product information, listed below.

Croscarmellose sodium Potassium hydroxide
Ethanol absolute Propylene glycol
Hyprolose Purified water
Hypromellose Shellac
Iron oxide red Strong ammonia solution
Isopropyl alcohol Tert-butyl alcohol
Magnesium stearate Titanium dioxide
Microcrystalline cellulose  

To date, there have been no medicine interactions identified with Lagevrio based on the limited data currently available.

Lagevrio is not recommended during pregnancy.

People of childbearing potential should use effective contraception for the duration of treatment and for four days after the last dose of Lagevrio. Men who are sexually active with a person of childbearing potential should use an effective contraception during treatment and for three months after treatment with Lagevrio.

Breastfeeding is not recommended during treatment and for four days after the last dose of Lagevrio.

The most common side effects of Lagevrio are diarrhoea, nausea and dizziness. These side effects can lead to significant morbidity in frail and elderly patients, including dehydration, delirium and increased falls risk. It is important older people who are administered Lagevrio are closely monitored. Patients should be advised to speak with their GP or prescribing physician if they are concerned about any side effects while taking the medication.

This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log